Cyclobenzaprine: Indications, Dosing, and Contraindications
Indications
Cyclobenzaprine is FDA-approved exclusively as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions 1. The drug should only be used for short periods of 2-3 weeks maximum, as adequate evidence for longer use does not exist and acute muscle spasm is typically self-limited 1.
Key Indication Details:
- Approved use: Acute painful musculoskeletal conditions with muscle spasm (low back pain, neck pain)
- Duration: Maximum 2-3 weeks of therapy
- Not indicated for: Spasticity from cerebral or spinal cord disease, cerebral palsy in children 1
The evidence base shows moderate superiority over placebo for short-term pain relief (2-4 days) in acute low back pain, though evidence for chronic pain is sparse and of lower quality 2.
Recommended Dosing
Start with 5 mg three times daily, which provides equivalent efficacy to 10 mg three times daily but with significantly fewer adverse effects 1, 3.
Standard Dosing Algorithm:
- Initial dose: 5 mg orally three times daily
- Maximum dose: 10 mg three times daily (only if 5 mg insufficient)
- Duration: 2-3 weeks maximum 1
Special Populations:
- Elderly patients: Use less frequent dosing; consider 5 mg once daily at bedtime given 2-fold higher steady-state concentrations 1, 4
- Hepatic impairment: Reduce dose or frequency; plasma concentrations are up to 2-fold higher in mild hepatic insufficiency 1, 4
- Gender: No significant dose adjustment needed despite minor pharmacokinetic differences 4
Clinical pearl: The 5 mg three times daily regimen demonstrates onset of relief within 3-4 doses and produces significantly less somnolence than 10 mg dosing while maintaining equivalent efficacy 3. Research shows that 88% of patients report at least mild improvement after 3 days and 93% after 7 days 5.
Contraindications
Cyclobenzaprine is absolutely contraindicated in four specific clinical scenarios 1:
Absolute Contraindications:
- Hypersensitivity to any component of the product
- MAO inhibitor use: Current use or within 14 days of discontinuation (risk of hyperpyretic crisis, seizures, and death)
- Acute myocardial infarction recovery phase, or patients with:
- Arrhythmias
- Heart block or conduction disturbances
- Congestive heart failure
- Hyperthyroidism
Safety Profile:
Skeletal muscle relaxants as a class are associated with 1.5-fold increased total adverse events and 2-fold increased CNS adverse events compared to placebo, though serious complications are rare 2. The most common adverse effects are:
Important caveat: The drug's structural similarity to tricyclic antidepressants underlies both its mechanism of action and its contraindications, particularly the dangerous interaction with MAO inhibitors and cardiac conduction effects 1.
Combination therapy note: Adding ibuprofen to cyclobenzaprine 5 mg three times daily provides no additional benefit over cyclobenzaprine monotherapy for acute neck or back pain with muscle spasm 5.